Sildosin as a Male Contraceptive Non Hormonal

Phase 1Not Yet RecruitingNCT07195097

Benha University200 enrolled

Overview

In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

200

Conditions

Contraception Use

Interventions

Oral intake of sildosinDRUG

Oral intake of sildosin in male non hormonal contraception

Oral intake of placeboOTHER

Intake of placebo to compare effecacy of other group

Eligibility

Sex: MALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male sexually active Exclusion Criteria: * male on oral contraceptives Male with female partner on contraceptives

Outcomes

Primary Outcomes

Pregnancy rate in people treated with sildosin as a male contraceptive

Pregnancy rate in people treated with sildosin as a male contraceptive treatment

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.